Agenus receives fast track designation for botensilimab and balstilimab in colorectal cancer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted fast track designation from the us food and drug administration (fda) for the investigation of the combination of botensilimab (agen1181) and balstilimab (agen2034).
AGEN Ratings Summary
AGEN Quant Ranking